Abstract
Over the last decade, major depressive disorder (MDD) has attracted great attention in the Western societies for mainly two reasons. First, epidemiological studies demonstrate a steady increase in the number of affected patients so that MDD will be one of the most disabling conditions worldwide in the near future. Second, preclinical and clinical science has early recognized the need for elaborating the cause and progression of MDD in order to improve treatment strategies. Progress in developing advanced technologies such as DNA microarrays and next-generation sequencing has allowed for rapidly acquiring detailed biochemical information about DNA polymorphisms and transcriptome profiles. These studies collectively show profound biochemical changes in affected individuals, and animal studies partly corroborate or complement the alterations identified in patients. In this review, we survey transcriptional changes in the course of MDD and the effects of antidepressant drugs on multiple disease-related transcriptional pathways. The combination of both potentially unravels additional mechanisms of disease aetiology which eventually represents a bottom-up approach for the discovery of newly-acting antidepressant drugs.
Keywords: Major depression, serotonin/norepinephrine re-uptake inhibitor, neuroplasticity, gene arrays, Depression, Antidepressant Transcriptomics, major depressive disorder, MDD, bipolar disorder, Glutamate Transporter , neurotoxicity, neurotrophin-3, CREB-associated CBP, hormone receptors, Neuropsychopharmacology
Current Psychopharmacology
Title:Interrelation of Major Depression and Antidepressant Transcriptomics
Volume: 1
Author(s): Jurgen Zschocke, Nils Christian Gassen and Theo Rein
Affiliation:
Keywords: Major depression, serotonin/norepinephrine re-uptake inhibitor, neuroplasticity, gene arrays, Depression, Antidepressant Transcriptomics, major depressive disorder, MDD, bipolar disorder, Glutamate Transporter , neurotoxicity, neurotrophin-3, CREB-associated CBP, hormone receptors, Neuropsychopharmacology
Abstract: Over the last decade, major depressive disorder (MDD) has attracted great attention in the Western societies for mainly two reasons. First, epidemiological studies demonstrate a steady increase in the number of affected patients so that MDD will be one of the most disabling conditions worldwide in the near future. Second, preclinical and clinical science has early recognized the need for elaborating the cause and progression of MDD in order to improve treatment strategies. Progress in developing advanced technologies such as DNA microarrays and next-generation sequencing has allowed for rapidly acquiring detailed biochemical information about DNA polymorphisms and transcriptome profiles. These studies collectively show profound biochemical changes in affected individuals, and animal studies partly corroborate or complement the alterations identified in patients. In this review, we survey transcriptional changes in the course of MDD and the effects of antidepressant drugs on multiple disease-related transcriptional pathways. The combination of both potentially unravels additional mechanisms of disease aetiology which eventually represents a bottom-up approach for the discovery of newly-acting antidepressant drugs.
Export Options
About this article
Cite this article as:
Zschocke Jurgen, Christian Gassen Nils and Rein Theo, Interrelation of Major Depression and Antidepressant Transcriptomics, Current Psychopharmacology 2012; 1 (4) . https://dx.doi.org/10.2174/2211556011201040284
DOI https://dx.doi.org/10.2174/2211556011201040284 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Overcoming the Blood-Brain Barrier for Chemotherapy: Limitations, Challenges and Rising Problems
Anti-Cancer Agents in Medicinal Chemistry Factors Interacting with HIF-1α mRNA: Novel Therapeutic Targets
Current Pharmaceutical Design Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery Recent Patents on Biomedical Devices and Nanomaterials for Hyperthermal Therapy of Cancer
Recent Patents on Nanomedicine Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma
Current Medicinal Chemistry Cancer Gene Therapy through Autonomous Parvovirus - Mediated Gene Transfer
Current Gene Therapy Kernelized Convex Hull based Collaborative Representation for Tumor Classification
Current Proteomics TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology Expression of P-gp in Glioblastoma: What we can Learn from Brain Development
Current Pharmaceutical Design Dihydromyricetin Reduces TGF-β Via P53 Activation-dependent Mechanism in Hepatocellular Carcinoma HepG2 Cells
Protein & Peptide Letters Cyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders
Current Pharmaceutical Design MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry Targeting Tumor Proteasome with Traditional Chinese Medicine
Current Drug Discovery Technologies SALL4: Engine of Cell Stemness
Current Gene Therapy Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design A Review on Chitosan in Drug Delivery for Treatment of Neurological and Psychiatric Disorders
Current Pharmaceutical Biotechnology Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry ADP-Ribosyl Cyclase as a Therapeutic Target for Central Nervous System Diseases
Central Nervous System Agents in Medicinal Chemistry Brain Tumor Detection from MR Images Employing Fuzzy Graph Cut Technique
Recent Advances in Computer Science and Communications Epidermal Growth Factor Receptor as a Target for Anti-Cancer Agent Design
Anti-Cancer Agents in Medicinal Chemistry